APA (7th ed.) Citation

Pujade-Lauraine, E., Selle, F., Scambia, G., Asselain, B., Marmé, F., Lindemann, K., . . . Redondo, A. (2023). Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): A phase IIIb trial. Annals of oncology, 34(12), . https://doi.org/10.1016/j.annonc.2023.09.3110

Chicago Style (17th ed.) Citation

Pujade-Lauraine, Éric, et al. "Maintenance Olaparib Rechallenge in Patients with Platinum-sensitive Relapsed Ovarian Cancer Previously Treated with a PARP Inhibitor (OReO/ENGOT-ov38): A Phase IIIb Trial." Annals of Oncology 34, no. 12 (2023). https://doi.org/10.1016/j.annonc.2023.09.3110.

MLA (9th ed.) Citation

Pujade-Lauraine, Éric, et al. "Maintenance Olaparib Rechallenge in Patients with Platinum-sensitive Relapsed Ovarian Cancer Previously Treated with a PARP Inhibitor (OReO/ENGOT-ov38): A Phase IIIb Trial." Annals of Oncology, vol. 34, no. 12, 2023, https://doi.org/10.1016/j.annonc.2023.09.3110.